Keywords: GlaxoSmithKline, Votrient, Soft tissue sarcoma, Europe, USA, Expanded indication

GlaxoSmithKline files for expanded Votrient use in USA and Europe

Article | 08 July 2011

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has submitted a variation to the Marketing Authorisation Application to the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in